Mark Smith - Finch Therapeutics CEO Director
| FNCHDelisted Stock | USD 8.51 0.19 2.18% |
Insider
Mark Smith is CEO Director of Finch Therapeutics Group
| Age | 37 |
| Phone | 617 229 6499 |
| Web | https://www.finchtherapeutics.com |
Mark Smith Latest Insider Activity
Tracking and analyzing the buying and selling activities of Mark Smith against Finch Therapeutics pink sheet is an integral part of due diligence when investing in Finch Therapeutics. Mark Smith insider activity provides valuable insight into whether Finch Therapeutics is net buyers or sellers over its current business cycle. Note, Finch Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Finch Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Mark Smith over three months ago Disposition of 2212 shares by Mark Smith of Smith Wesson at 15.21 subject to Rule 16b-3 | ||
Mark Smith over six months ago Acquisition by Mark Smith of 8490 shares of Phreesia subject to Rule 16b-3 | ||
Mark Smith over six months ago Disposition of 28800 shares by Mark Smith of Smith Wesson subject to Rule 16b-3 | ||
Mark Smith over a year ago Payment of 2268 shares by Mark Smith of Smith Wesson subject to Rule 16b-3 |
Finch Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2194) % which means that it has lost $0.2194 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6264) %, meaning that it created substantial loss on money invested by shareholders. Finch Therapeutics' management efficiency ratios could be used to measure how well Finch Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Finch Therapeutics Group currently holds 30.13 M in liabilities with Debt to Equity (D/E) ratio of 0.35, which is about average as compared to similar companies. Finch Therapeutics has a current ratio of 7.13, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Finch Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Finch Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Finch Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Finch to invest in growth at high rates of return. When we think about Finch Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Daniel Hicklin | Werewolf Therapeutics | 61 | |
| Michael Carruthers | Edgewise Therapeutics | 67 | |
| Lance Laing | Celcuity LLC | 63 | |
| Ramtin MD | RenovoRx | 59 | |
| CPA CPA | Stoke Therapeutics | 63 | |
| FACC MD | Stoke Therapeutics | 61 | |
| Jennifer Champoux | Monte Rosa Therapeutics | N/A | |
| Andrew Hirsch | C4 Therapeutics | 53 | |
| Gerald Goodman | Nutriband | 77 | |
| Silvia Buonamici | Monte Rosa Therapeutics | N/A | |
| Phil JD | Monte Rosa Therapeutics | 45 | |
| Jason Davis | Virax Biolabs Group | 53 | |
| Denise Carter | Quoin Pharmaceuticals Ltd | 56 | |
| Michael Myers | Quoin Pharmaceuticals Ltd | 63 | |
| James Ahlers | RenovoRx | 60 | |
| Evan Hecker | Ikena Oncology | N/A | |
| MD FACC | Longeveron LLC | 62 | |
| Chester III | Revelation Biosciences | 45 | |
| Christopher Frankenfield | Xilio Development | 43 | |
| Lauren White | C4 Therapeutics | N/A | |
| Ellen MBA | Werewolf Therapeutics | 49 | |
Management Performance
| Return On Equity | -0.63 | ||||
| Return On Asset | -0.22 |
Finch Therapeutics Leadership Team
Elected by the shareholders, the Finch Therapeutics' board of directors comprises two types of representatives: Finch Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Finch. The board's role is to monitor Finch Therapeutics' management team and ensure that shareholders' interests are well served. Finch Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Finch Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD MBA, Chief Officer | ||
| Lance CPA, Chief Officer | ||
| Bryan MBA, Chief Officer | ||
| Sonia Timberlake, VP Research | ||
| CFA CFA, Principal COO | ||
| Mark Smith, CEO Director | ||
| Alka Batycky, Chief Officer | ||
| JD Esq, Chief Sec | ||
| Matthew JD, Chief Officer | ||
| James Sigler, Ex CMC | ||
| James MBA, Executive CMC |
Finch Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Finch Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.63 | ||||
| Return On Asset | -0.22 | ||||
| Current Valuation | 10.74 M | ||||
| Shares Outstanding | 1.61 M | ||||
| Shares Owned By Insiders | 53.48 % | ||||
| Shares Owned By Institutions | 11.35 % | ||||
| Number Of Shares Shorted | 19.2 K | ||||
| Price To Book | 0.14 X | ||||
| Price To Sales | 30.46 X | ||||
| Revenue | 107 K |
Currently Active Assets on Macroaxis
| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin | |
| ADA | Cardano | |
| XRP | XRP |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Consideration for investing in Finch Pink Sheet
If you are still planning to invest in Finch Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Finch Therapeutics' history and understand the potential risks before investing.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Stocks Directory Find actively traded stocks across global markets | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |